Analysis of a New Biomarker for Prostate Cancer Diagnosis

N/AUnknownNCT01819740

Corporacion Parc Tauli28 enrolled

Overview

The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Patients With Suspected Prostate Cancer

Interventions

determine the levels of the "HEM" substance in seminal plasmaOTHER

Eligibility

Sex: MALEMin age: 45 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical or laboratory suspected of prostate cancer Exclusion Criteria: * Inability to ejaculate

Locations (1)

Hospital Universitario Parc Taulí

Sabadell, Barcelona, Spain

Outcomes

Primary Outcomes

substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry

Time frame: 1 hour

Central Contacts

Miriam Barrio-Muñoz

CONTACT

34 93 723 10 10 mbarrio6@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.